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Abstract 
Hypovitaminosis D is highly prevalent in chronic kidney disease (CKD). Recently, vitamin D 
has sparked widespread interest because of its potential favorable benefits on cardiovascular 
disease (CVD). Evidence from clinical studies and animal models supports the existence of 
biphasic cardiovascular effects of vitamin D, in which lower doses suppress CVD and higher 
doses stimulate CVD. However, the mechanism for the different effects remains unclear. 
Fibroblast growth factor-23 (FGF-23) is a recently identified member of the FGF family, and 
thought to be actively involved in renal phosphate and vitamin D homeostasis. More specif-
ically, Vitamin D stimulates FGF-23 secretion and is inhibited by increased FGF-23. Given this 
background, we hypothesize that FGF-23 may provide a unique tool to explain the biphasic 
cardiovascular effects of vitamin D in CKD. The data presented in this review support the 
hypothesis that FGF-23 may be linked with the high cardiovascular risk in CKD through ac-
celerating the onset of vascular calcification, secondary hyperparathyroidism, left ventricular 
hypertrophy and endothelial dysfunction. Therefore, modulation of FGF-23 may become a 
potential therapeutic target to lowing cardiovascular risk in CKD. Several clinical interven-
tions, including decreased phosphate intake, phosphate binders, cinacalcet plus concurrent 
low-dose vitamin D, C-terminal tail of FGF-23 and renal transplantation, have been employed 
to manipulate FGF-23. 
Key words: Fibroblast growth factor-23; Hypovitaminosis D; Cardiovascular disease; Phosphate; 
Left ventricular hypertrophy 
Introduction 
Vitamin D refers to a group of compounds that 
have  antirachitic  activity.  During  the  period  of  its 
discovery, it was recognized that there were two an-
tirachitic factors with distinct structures, vitamin D3 
and vitamin D2. Vitamin D3 can be produced in the 
vertebrate skin as 7-dehydrocholesterol on exposure 
to  ultraviolet-B  from  the  sun,  whereas  vitamin  D2 
comes from plants [1]. Both vitamin D3 and vitamin 
D2 can be further modified by corresponding enzymes 
to  produce  different  vitamin  D  metabolites.  After 
vitamin  D  enters  the  body,  it  circulates  bound  to 
vitamin D-binding protein and is rapidly converted 
into its major circulating form, 25-hydroxyvitamin D 
[25-(OH)D], by the liver. 25-(OH)D is filtered at the 
glomerulus and actively reabsorbed into renal tubular 
cells via megalin and cubulin, where it is converted 
into  the  potent  hormone  1,25-dihydroxyvitamin  D 
[1,25-(OH)2D]  by  the  enzyme  1α-hydroxylase  [2]. 
25-(OH)D is the nutritional form of vitamin D. Serum 
25-(OH)D is regarded as the best indicator of vitamin 
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D status, because it  has a longer biological half-life 
than  1,25-(OH)2D,  and  circulates  in  much  higher 
concentrations. In contrast, 1,25-(OH)2D is the active 
form of vitamin D. Circulating levels of 1,25-(OH)2D 
chiefly depend on the ability of renal 1α-hydroxylase 
to convert 25-(OH)D into 1,25-(OH)2D. This ability is 
decreased  by  a  reduction  in  the  nephron  mass. 
Therefore, in this review, when vitamin D status was 
mentioned, the “vitamin D” referred to “25-(OH)D”; 
when vitamin D therapy was mentioned, the “vitamin 
D” referred to “1,25-(OH)2D”. 
Circulating  1,25-(OH)2D  enters  the  target  cells, 
either in its free form or facilitated by megalin, and 
binds to the vitamin D receptor (VDR) in the cyto-
plasm, which then translocates into the nucleus and 
heterodimerizes  with  the  retinoic  X  receptor  (RXR). 
The  1,25-(OH)2D-VDR-RXR  complex  then  binds  to 
vitamin D response elements (VDRE) on DNA to in-
crease transcription of vitamin D-regulated genes [3]. 
The classical physiological function of vitamin D is to 
maintain  the  calcium  and  phosphate  homeostasis, 
accomplished by close coordination with parathyroid 
hormone (PTH) [4, 5]. 
Vitamin D status in chronic kidney disease 
(CKD) 
The Kidney Disease Outcome Quality Initiative 
(K/DOQI)  has  recently  raised  concerns  of  a  high 
prevalence  of  hypovitaminosis  D  in  patients  with 
CKD [6]. According to serum 25-(OH)D levels, 76% of 
CKD  patients  display  either  vitamin  D  deficiency 
[42%;  25-(OH)D≤15ng/ml]  or  insufficiency  [34%; 
15ng/ml<25-(OH)D≤30ng/ml] [7]. What's worse, se-
rum 25-(OH)D is below the recommended sufficiency 
values  in  >90%  of  patients  if  they  progress  to 
end-stage renal disease (ESRD) [8]. CKD patients are 
at  particular  risk  of  25-(OH)D  deficiency,  including 
reduced  sun  exposure,  impaired  production  of  the 
25-(OH)D  precursor  molecule  and  reduced  dietary 
intake [9]. In contrast to 25-(OH)D, circulating levels 
of 1,25-(OH)2D chiefly depend on the ability of renal 
1α-hydroxylase  to  convert  25-(OH)D  into 
1,25-(OH)2D.  This  ability  is  decreased  because  of  a 
reduction  in  the  nephron  mass  [10].  It  is  therefore 
necessary to modulate the vitamin D signaling using 
1,25-(OH)2D  or  its  analogues  to  compensate  for  the 
compromised  vitamin  D  status  which  occurs  in  all 
stages  of  CKD,  so  that  the  classical  functions  of 
1,25-(OH)2D may be addressed [11]. 
Biphasic cardiovascular effects of vitamin 
D in CKD 
The  increased  risk  of  cardiovascular  disease 
(CVD)  in  patients  with  CKD  has  been  well  docu-
mented [12, 13]. Although it is true that many tradi-
tional  cardiovascular  risk  factors  are  corrected  in 
CKD, the results of intervention may not be as effica-
cious  as  those  obtained  in  the  general  population. 
Thus, there may also be a unique milieu established in 
CKD, which leads to excess CVD burden by mecha-
nisms  that  are  as  yet  not  fully  understood  [14, 15]. 
Recently, vitamin D has sparked widespread interest 
because of its potential beneficial effects on CVD [16, 
17]. A historical cohort study carried out by Teng et al. 
showed  that  incident  chronic  hemodialysis  patients 
treated with activated injectable vitamin D had a sig-
nificant survival advantage over a comparable group 
of chronic hemodialysis patients who did not; cardi-
ovascular-related  mortality  rates  were  7.6  per  100 
person-years in the injectable vitamin D group, com-
pared  with  14.6  per  100  person-years  in  the 
non-vitamin  D  group  [18].  In  stratified  analyses  by 
vitamin D therapy, after adjustment for age, sex, PTH 
and albumin, the odds ratio (OR) of all-cause mortal-
ity was 2.2 for 25-(OH)D levels <10ng/ml compared 
with 25-(OH)D levels >30ng/ml; in a similar stratified 
model  of 1,25-(OH)2D, the adjusted OR of all-cause 
mortality was 3.1 for 1,25-(OH)2D levels of 6-13pg/ml 
compared with 1,25-(OH)2D levels >13pg/ml [19]. A 
meta-analysis examined 9 randomized controlled tri-
als and also found an 8% reduction in cardiovascular 
mortality  with  supplementation  of  very  modest 
amounts of vitamin D (~500IU) [20]. More specifically, 
two other studies compared mortality among hemo-
dialysis  patients  receiving  different  types  of 
1,25-(OH)2D formulations, and found that  mortality 
was  lower  among  patients  receiving  doxercalciferol 
(15.4 per 100 person-years) and paricalcitol (15.3 per 
100 person-years) versus calcitriol (19.6 per 100 per-
son-years) [21, 22]. However, the study of Tentori et al. 
raised  questions  about  the  previously  reported  sur-
vival  advantage  associated  with  vitamin  D  therapy 
[23].  In addition, an earlier and smaller study from 
India also did not show any benefit from having op-
timal levels of 25-(OH)D in subjects with established 
CVD; in contrast, the authors reported that very high 
levels of 25-(OH)D (>89ng/ml) were associated with 
an increased risk of ischemic heart disease [24]. Inter-
estingly, consistent with these findings in humans, an 
animal model of CKD showed that the administration 
of clinically relevant doses of vitamin D reduced arte-
rial calcification [25]; while in another study, rats fed 
on  a  diet  rich  in  cholesterol  and  extremely  high  in 
vitamin  D  (1.8  million  units/kg)  developed  greater 
arterial calcification [26]. Thus, evidence from clinical 
studies and animal models supports the existence of 
biphasic cardiovascular effects of vitamin D, in which Int. J. Biol. Sci. 2012, 8 
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lower doses suppress CVD and higher doses stimu-
late CVD [27]. However, the mechanism for the dif-
ferent effects remains unclear. 
Molecular structure and physiological 
function of fibroblast growth factor-23 
(FGF-23) 
FGF-23 is a 32-kDa protein with 251 amino acids 
that is synthesized and secreted by bone cells, mainly 
osteoblasts. It is composed of an amino-terminal sig-
nal  peptide  (residues  1-24),  an  “FGF-like  sequence” 
(residues  25-180),  and  a  carboxyl-terminal  extended 
sequence  (residues  181-251)  [28,  29].  Unlike  most 
other members of the FGF family, since FGF-23 con-
tains a signal peptide and has low affinity for heparin, 
it can be distributed throughout the body in the blood 
and act at many distant sites, such as the kidney [30]. 
FGF-23 signals with highest efficacy through four FGF 
receptors (FGFR) bound to the transmembrane pro-
tein Klotho as a coreceptor. Of the four members of 
the FGFR family, FGFR1 and FGFR4 are expressed in 
the distal tubule, FGFR2 is expressed mainly in the 
macula densa, whereas FGFR3 is expressed both in 
the  proximal  tubule  and  in  the  distal  tubule  [31]. 
FGFR2 is not a likely candidate for mediating FGF-23 
effects  in  the  kidney,  because  it  does  not  bind  to 
FGF-23 [32]. Furthermore, a recent study showed that 
neither FGFR3 nor FGFR4 is the principal mediator of 
FGF-23  effects  in  the  kidney  [33],  suggesting  that 
FGFR1 is the only remaining target for FGF-23 [34]. 
FGF-23 induces urinary phosphate excretion by sup-
pressing the abundance of the Na/Pi IIa and IIc co-
transporters  in  the  brush  border  of  renal  proximal 
tubules  [35].  In  animal  studies,  transgenic  mice 
over-expressing human or mouse FGF-23 have severe 
renal phosphate wasting because of the inhibition of 
renal  Na/Pi  cotransporter  activity  [36,  37],  whereas 
FGF-23  inactivation  (FGF-23  null  mice  and  normal 
mice treated with FGF-23 blocking antibodies) leads 
to hyperphosphatemia [38, 39]. A pioneer study pub-
lished in Nature Genetics revealed that missense mu-
tations  in  FGF-23  gene  are  responsible  for  human 
variants  of  hypophosphatemic  rickets  [40].  In  addi-
tion,  FGF-23  also  suppresses  1,25-(OH)2D  via 
down-regulation  of  1α-hydroxylase  and 
up-regulation  of  24-hydroxylase  which  converts 
1,25-(OH)2D into more hydrophilic metabolites with 
lesser biological activity [41, 42]. On the contrary, the 
administration  of  1,25-(OH)2D  increases  circulating 
FGF-23  levels,  apparently  due  to  a  direct  action  of 
vitamin D on FGF-23 via a VDRE located upstream of 
the FGF-23 promoter, which may be related to future 
resistance to vitamin D therapy [43, 44]. 
Metabolism of FGF-23 in CKD 
The  elevation  of  serum  FGF-23  is  a  common 
feature in CKD. This occurs as early as stage 2 CKD, 
long  before  any  changes  in  calcium,  phosphate,  or 
PTH  are  apparent  [45].  By  the  time  patients  reach 
ESRD, FGF-23 concentrations are often 100- to 1000- 
fold above the normal range [46], and moreover, cir-
culating FGF-23 in ESRD patients is mostly intact and 
biologically  active  [47].  Three  possible  explanations 
could account for the event. First, it appears that the 
massive  elevations  in  FGF-23  levels  in  CKD  reflect 
both increased secretion into and decreased removal 
from the circulation. In the report of Bacchetta et al. 
[48],  treatment  with  corticosteroids  could  activate 
osteocytes in pediatric CKD patients, and then signif-
icantly stimulate FGF-23 synthesis. On the other hand, 
Westerberg  et al.  [49]  found  that  FGF-23  levels  and 
estimated glomerular filtration rate (eGFR) were in-
versely correlated among individuals with CKD stage 
4-5.  Second,  the  other  cause  of  increased  levels  of 
FGF-23 may be a compensatory phenomenon to the 
phosphate retention seen in CKD. Perwad et al. [50] 
fed  normal  mice  with  low-,  medium-,  or 
high-phosphate diet for 5 days and measured circu-
lating FGF-23 concentrations using an intact FGF-23 
assay. In mice fed with high- (1.65%) phosphate in-
take,  the  mean  serum  FGF-23  concentration  was 
65±6.5 pg/ml, a value 7-fold higher than that in mice 
fed with  the low- (0.02%) phosphate intake, 9.9±1.0 
pg/ml. Ito et al. [51] expressed FGF-23 promoter con-
structs in transiently transfected K562 cells in media 
with various concentrations of phosphate and showed 
an increase in promoter activity with high-phosphate 
medium. Last but most important, vitamin D therapy 
in patients with CKD may also contribute to the in-
creased  serum  levels  of  FGF-23.  In  5/6  nephrecto-
mized  rats,  intravenous  administration  of 
1,25-(OH)2D,  three  times  a  week  for  2  weeks, 
dose-dependently increased serum FGF-23 [52].  
FGF-23 may serve as a novel risk marker for the 
cardiovascular mortality in CKD [53]. The ArMORR 
study  revealed  that  high  FGF-23  levels  in  patients 
starting hemodialysis were an independent predictor 
of 1-year mortality after adjustment for serum phos-
phate and PTH levels; and in a multivariable adjusted 
model,  subjects  whose  FGF-23  levels  were  in  the 
highest quartile had nearly a 600% increase in risk as 
compared with subjects in the lowest quartile [54]. In 
addition, in the case of FGF-23, a special characteristic 
could favor its use as a marker: the fact that FGF-23 
concentrations  remain  stable  throughout  the  day  in 
patients with CKD [55]. Although the mechanistic link 
between elevated FGF-23 levels and increased cardi-Int. J. Biol. Sci. 2012, 8 
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ovascular mortality in CKD remains to be answered, 
the data present below focusing on vascular calcifica-
tion,  secondary  hyperparathyroidism  (SHPT),  left 
ventricular hypertrophy (LVH), and endothelial dys-
function may be supportive of the pathophysiological 
sequence of vitamin D supplement – FGF-23 excess – 
cardiovascular susceptibility (Figure 1). 
FGF-23 and vascular calcification 
Vascular calcification is very prevalent in CKD, 
especially in ESRD. The mechanisms of vascular cal-
cification  are  hyperphosphatemia  and  elevated  cal-
cium × phosphate product. Vascular calcification in-
duces stiffening of the vessel wall and reduces vas-
cular compliance, which has been found to be predic-
tive of cardiovascular mortality [56]. FGF-23, a major 
phosphatonin, decreases serum phosphate concentra-
tions  by  directly  reducing  renal  reabsorption,  and 
therefore  prevents  vascular  calcification  in  physio-
logical conditions. FGF-23 null mice on a regular diet 
develop a mineral profile similar to patients who suf-
fer  from  ESRD  and  are  treated  with  high-dosage 
vitamin  D,  namely,  elevated  serum  calcium,  phos-
phate and 1,25-(OH)2D levels along with ubiquitous 
vascular calcification and decreased survival [38, 57]. 
In  the  clinical  investigation  undertaken  by  Wes-
seling-Perry et al. [58], irrespective of residual renal 
function, serum FGF-23 levels correlated with phos-
phate and calcium × phosphate product. In another 
study,  Gutierrez  et al.  [59]  divided  80  patients  into 
four  CKD  groups  according  to  the  eGFR,  and  ob-
served that serum levels of FGF-23 increased as kid-
ney function decline, whereas phosphate values did 
not  become  abnormal  until  eGFR  fell  below  30 
ml/min/1.73m2.  Thus,  it  seems  that  during  early 
stages of CKD, FGF-23 may contribute to maintaining 
the serum phosphate levels within the normal range. 
This compensation for decreased nephron mass may 
be overcome by severe renal failure when overt hy-
perphosphatemia  and  vascular  calcification  develop 
despite markedly increased FGF-23 levels [60]. There 
may be a feedback loop existing between serum vit-
amin D, FGF-23 and mineral disorder. FGF-23 is both 
the cause of abnormal serum calcium and phosphate 
levels and their consequence [61]. 
 
 
 
Figure 1. The pathophysiological sequence of vitamin D supplement – FGF-23 excess – cardiovascular susceptibility in CKD. 
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FGF-23 and SHPT 
As kidney function declines, the elevated serum 
PTH  concentrations  are  frequently  the  earliest  de-
tectable  abnormality  [62].  Individuals  with  elevated 
PTH concentrations are at higher risk of cardiovascu-
lar mortality. According to the statistical data report-
ed by Hagström et al. [63], in a community-based co-
hort of 958 elderly men, a 1-SD increase in serum PTH 
was associated with a 37% to 38% higher risk for car-
diovascular mortality in the crude and multivariable 
models. Several mechanisms may account for the link 
between  PTH  and  cardiovascular  mortality.  First, 
PTH is directly implicated in atherogenesis through 
vascular  calcification  and  vascular  remodeling  [64, 
65]. Second, PTH seems also to have detrimental ef-
fects on the myocardium through induction of LVH, 
cardiac calcification and fibrosis [66-68]. Third, SHPT 
may participate in the pathophysiological mechanism 
of hyperlipidemia seen in chronic renal failure [69]. 
Fourth, higher PTH is related with both established 
cardiovascular  risk  factors  and  more  recently  de-
scribed  risk  factors  such  as  inflammation  markers, 
renal dysfunction and cardiac pathology [63, 70-72]. 
Finally, because PTH is one of the pivotal regulatory 
hormones  in  the  mineral  homeostasis,  it  is  possible 
that the serum levels of PTH reflect other abnormali-
ties along the same pathway such as vitamin D defi-
ciency, hypercalcemia, hyperphosphatemia and renal 
failure, which predisposes to a higher risk for cardi-
ovascular mortality [63]. 
FGF-23 is located upstream of the PTH molecule. 
A study that measured both FGF23 and PTH in pa-
tients with early CKD and healthy controls suggested 
that  FGF23  excess  precedes  PTH  excess,  because 
FGF23 levels were already twice normal and signifi-
cantly  higher  in  patients  with  CKD,  whereas  PTH 
levels  were  normal  and  not  significantly  different 
between patients with CKD and healthy participants 
[73]. Up-regulation of FGF-23 in patients with CKD 
inhibits  renal  1α-hydroxylase  and  results  in  early 
1,25-(OH)2D  deficiency,  which  may  initiate  the  de-
velopment  of  SHPT  [74].  Two  representative  ap-
proaches have been employed to identify the signifi-
cant relationship between FGF-23 and PTH in vivo. 
Animal models of expression of FGF-23 demonstrate 
diffuse  parathyroid  hyperplasia  and  SHPT  [37]; 
FGF-23 null mice have low PTH concentrations due to 
very high serum calcium and 1,25-(OH)2D levels [75]. 
However, the action of FGF-23 on PTH is variable in 
vitro. Krajisnik et al. [76] treated parathyroid cells with 
a  stabilized  form  of  recombinant  FGF-23 
[FGF-23(R176Q)] and found that FGF-23(R176Q) ex-
erted an obvious effect on cell apoptosis and reduced 
the PTH mRNA level in a dose-dependent manner in 
the concentration rang of 400~2000pg/ml; when the 
FGF-23(R176Q) concentrations were over 2000pg/ml, 
they  did  not  detect  any  significant  effect  on  cell 
apoptosis, whereas a small but significant increase in 
cell  proliferation  was  observed.  In  another  study, 
Ben-Dov et al. showed that FGF-23 suppressed both 
PTH secretion and PTH gene expression in vitro rat 
parathyriod  cultures  through  the  mitogen-activated 
protein kinase pathway [77]. The Ben-Dov and Kraj-
isnik studies are the only data that isolate direct ef-
fects  of  FGF23  on  the  parathyroid,  independent  of 
circulating mineral content. Either provide some evi-
dence  to  support  the  statement  that  “FGF23  sup-
presses  PTH”.  Conversely,  PTH  may  stimulate 
FGF-23 secretion by osteoblasts, because the FGF-23 
levels of patients with primary hyperparathyroidism 
are  increased,  which  may  be  reduced  by  parathy-
roidectomy [78]. The mechanisms by which PTH me-
diates changes in FGF-23 expression remain unclear 
and may be ascribed to either direct effects on FGF-23 
gene expression itself or mediation through other po-
tential  regulators  of  FGF-23  [79].  Therefore,  FGF-23 
stimulates  PTH  in  vivo  or  in  CKD  individuals, 
whereas  suppresses  PTH  in  vitro,  and  is  also  in-
creased by excess PTH [80]; FGF-23 is an important 
predictor of future SHPT and subsequent cardiovas-
cular  mortality  in  patients  undergoing  CKD,  espe-
cially when serum phosphate and PTH levels are in 
the normal range [81]. 
FGF-23 and LVH 
LVH  is  a  prevalent  manifestation  of  CVD  and 
also an independent risk factor for mortality in pa-
tients with CKD [82, 83]. Approximately 40% of pa-
tients with predialysis CKD and up to 80% of patients 
initiating hemodialysis manifest LVH [84, 85]. Insuf-
ficiency of cardiac diastolic and contractive functions, 
inappropriate  activation  of  the  ren-
in-angiotensin-aldosterone system, alteration of fluid 
balance and disturbance of collagen are identified as 
the major determinants of LVH in CKD [86]. Several 
near recent studies have demonstrated that elevated 
FGF-23 may be also involved in the LVH onset [47, 
87].  In  maintenance  hemodialysis  patients,  serum 
FGF-23  levels  were  significantly  correlated  with 
higher mean left ventricular mass index (LVMI) and 
lower  mean  ejection  fraction,  irrespective  of  B-type 
natriuretic peptide and cardiac troponin T [88]. And 
in  transgenic  mice  overexpressing  human  FGF-23, 
interventricular septum thickness diastolic, left ven-
tricular posterior wall thickness diastolic and LVMI 
relative to body weight were significantly increased, 
which  may  be  attributed  to  the  impaired  vascular Int. J. Biol. Sci. 2012, 8 
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reactivity  and  down-regulation  of  vasoconstrictor 
receptors (α1-ARs and AT1A) [89]. The cardiac hyper-
trophic effects of FGF-23 are mediated by FGFR acti-
vation and could be blocked in vitro by the FGFR in-
hibitor PD173074, but do not require Klotho as core-
ceptor  [90].  Furthermore,  matrix  metalloproteinases 
dysmetabolism may also act as a close link between 
elevated FGF-23 and LVH in patients with CKD [91]. 
FGF-23 and endothelial dysfunction 
CKD  is  now  considered  a  typical  situation  of 
chronic inflammatory state. C-reactive protein (CRP), 
a nonspecific marker of inflammation, is described as 
a fundamental biomarker for endothelial dysfunction 
in  patients  with  CKD  [92].  Endothelial  dysfunction 
usually describes binding of monocytes to the endo-
thelial surface, down-regulation of nitric oxide activ-
ity, reduced dilatory capacities and an early event of 
arteriosclerosis [93]. Although some data from clinical 
observations have suggested that FGF-23 is associated 
with the elevated levels of CRP in CKD patients [94, 
95], there is scant direct evidence supporting the in-
duction of endothelial dysfunction by FGF-23. To the 
best of our knowledge, pioneer work was conducted 
by Mirze et al. [96] at the Uppsala University Hospital. 
His group found that FGF-23 could reduce endothe-
lium-dependent vasodilation both in healthy subjects 
and  in  subjects  with  eGFR<60  ml/min/1.73m2.  A 
more recent report also demonstrated that  the high 
log FGF-23 was a significant independent risk factor 
of the increased carotid artery intima-media thickness 
in 128 maintenance hemodialysis patients [97]. How-
ever, there is some data suggesting that Klotho, the 
cofactor of FGF-23, can regulate endothelial function. 
In  the  study  of  Hu  et al.  [98],  despite  induction  of 
CKD, Klotho transgenetic mice had preserved levels 
of Klotho and much less vascular calcification com-
pared  with  wild-type  mice  with  CKD;  inversely, 
Klotho-haploinsufficient  mice  with  CKD  had  unde-
tectable levels of Klotho and severe vascular calcifica-
tion. It is possible that part of the beneficial effects of 
Klotho  on  endothelial  function  in  CKD  result  from 
improvement  of  FGF-23  signal  transduction  [99]. 
Therefore, further studies in vitro are needed to clar-
ify whether FGF-23 is a marker or a potential initia-
tion for endothelial dysfunction in CKD. 
Perspectives 
Taken  as  a  whole,  the  data  presented  above 
which  come  from  observational  or  experimental 
studies support the hypothesis that FGF-23 may help 
to explain the biphasic cardiovascular effects of vita-
min D in CKD, according to the cross actions between 
FGF-23 and the multiple metabolic pathways (vascu-
lar  calcification,  SHPT,  LVH  and  endothelial  dys-
function). Therefore, modulation of FGF-23 may be-
come a potential therapeutic target for the lowering of 
cardiovascular risk in CKD. 
Several  clinical  interventions  have  been  em-
ployed  to  manipulate  FGF-23.  (1)  Decreased  phos-
phate  intake:  Ferrari  et  al.  [100]  measured  FGF-23 
concentrations  in  29  healthy  young  men  who  were 
treated sequentially with 5 days of dietary phosphate 
restriction, followed by an equilibration period, then 5 
days  of  a  high-phosphate  diet.  The  mean  serum 
FGF-23  concentration  decreased  29.1±6.5%  during 
phosphate restriction, and increased 31.1±9.5% during 
phosphate  supplementation.  In  addition,  dietary 
phosphate modification can also regulate 1,25-(OH)2D 
production, mediated in part by changes in circulat-
ing FGF-23. Antoniucci et al. studied 13 healthy men 
during  a  4-week  dietary  phosphate  intervention 
study, and found that serum FGF-23 concentrations 
decreased  significantly  from  30.7±8.7  pg/ml  during 
phosphate supplementation to 19.6±7.0 pg/ml during 
phosphate  restriction,  accompanied  with  increased 
1,25-(OH)2D levels from 29±10 pg/ml to 40±16 pg/ml 
[101].  (2)  Phosphate  binders:  A  short-term  6-week 
dose  titration  study  evaluated  the  effects  of  two 
phosphate binders, sevelamer hydrochloride and cal-
cium acetate, on FGF-23 levels in patients with CKD 
stages 3 to 4. Sevelamer-treated patients presented a 
significant reduction in FGF-23 (107 pg/ml at baseline 
versus 54 pg/ml at the 6th week), whereas this was not 
observed in calcium-treated patients [102]. Conform-
ably, Gonzalez-Parra et al. showed that serum FGF-23 
concentrations in 18 patients with CKD stages 3 were 
significantly decreased after 4 weeks treatment with 
lanthanum carbonate [103]. Even more excitingly, in a 
1-year  prospective  observational  study  of  incident 
hemodialysis  patients,  treatment  with  phosphate 
binders  was  associated  with  a  significant  survival 
advantage compared with no treatment (13.6 versus 
23.5 deaths per 100 person-years) [104]. (3) Cinacalcet 
and concurrent low-dose  vitamin D: Wetmore et al. 
[105] used samples from ACHIEVE trial to perform a 
per-protocol  analysis  of  the  effects  of  treatment  on 
FGF-23, and they found that the treatment regimen 
using Cinacalcet plus fixed low-dose calcitriol analogs 
could  result  in  a  relative  decrease  in  FGF-23  levels 
compared with an approach using escalating doses of 
calcitriol analogs alone, after a 27-week intervention 
period  (-9.7%  versus  4.1%).  (4)  C-terminal  tail  of 
FGF-23:  Goetz  et  al.  [106]  injected  the  isolated 
72-residue-long C-terminal tail of FGF-23 into healthy 
rats and demonstrated that it could block the patho-
genic  actions  of  intact  FGF-23,  which  may  hold 
promise  of  providing  the  first  causative  pharma-Int. J. Biol. Sci. 2012, 8 
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cotherapy.  C-terminal  tail  of  FGF-23,  generating  an 
endogenous inhibitor of intact FGF-23, removes the 
binding site for the binary FGFR-Klotho complex. (5) 
Renal  transplantation:  Economidou  et  al.  [107]  per-
formed  a  prospective  study  to  investigate  FGF-23 
levels in 18 patients with ESRD before and after renal 
transplantation.  Compared  with  pretransplantation, 
FGF-23  levels  decreased  by  89%  at  the  end  of  3 
months  posttransplantation,  and  moreover,  all  pa-
tients  had  normal  FGF-23  levels  (<50  pg/ml)  at  12 
months posttransplantation. The excessive and rapid 
reduction may be due to increased urinary excretion 
[108]. 
Acknowledgments 
This study was supported by the National Nat-
ural Science Foundation of China (No. 81000306) and 
the Post-Doctoral Foundation of Anhui Medical Uni-
versity (No. 2009KJ02). 
Competing Interests 
The  authors  have  declared  that  no  competing 
interest exists. 
References 
1.  Beale MG, Chan JC, Oldham SB, et al. Vitamin D: the discovery of 
its metabolites and their therapeutic applications. Pediatrics. 1976; 
57: 729-41. 
2.  Stamp  TC.  Vitamin  D  metabolism.  Recent  advances.  Arch  Dis 
Child. 1973; 48: 2-7. 
3.  Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hor-
mone and its nuclear receptor: molecular actions and disease states. 
J Endocrinol. 1997; 154: S57-73. 
4.  Breidenbach A, Schlumbohm C, Harmeyer J. Peculiarities of vita-
min D and of the calcium and phosphate homeostatic system in 
horses. Vet Res. 1998; 29: 173-86. 
5.  Amizuka N, Kwan MY, Goltzman D, et al. Vitamin D3 differentially 
regulates parathyroid hormone/parathyroid hormone-related pep-
tide receptor expression in bone and cartilage. J Clin Invest. 1999; 
103: 373-81. 
6.  National Kidney Foundation. K/DOQI clinical practice guidelines 
for bone metabolism and disease in chronic kidney disease. Am J 
Kidney Dis. 2003; 42: S1-201. 
7.  Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival 
independently of vascular calcification in chronic kidney disease. 
Clin J Am Soc Nephrol. 2009; 4: 1128-35. 
8.  London GM, Guérin AP, Verbeke FH, et al. Mineral metabolism and 
arterial  functions  in  end-stage  renal  disease:  potential  role  of 
25-hydroxyvitamin  D  deficiency.  J  Am  Soc  Nephrol.  2007;  18: 
613-20. 
9.  Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic 
kidney  disease:  in  search  of  the  therapeutic  window.  Pediatr 
Nephrol. 2010; 25: 2413-30. 
10.  Williams S, Malatesta K, Norris K. Vitamin D and chronic kidney 
disease. Ethn Dis. 2009; 19: S5-S8-S11 
11.  Hu P, Hu B, Wang J, et al. Modulation of vitamin D signaling is a 
potential therapeutic target to lower cardiovascular risk in chronic 
kidney disease. Med Sci Monit. 2011; 17: HY14-20. 
12.  Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid 
arteriopathy  in  young  adults  with childhood-onset  chronic renal 
failure. Circulation. 2002; 106: 100-5. 
13.  Mitsnefes MM. Cardiovascular complications of pediatric chronic 
kidney disease. Pediatr Nephrol. 2008; 23: 27-39. 
14.  Rakhit DJ, Marwick TH, Armstrong KA, et al. Effect of aggressive 
risk factor modification on cardiac events and myocardial ischaemia 
in patients with chronic kidney disease. Heart. 2006; 92: 1402-8. 
15.  Kaisar MO, Isbel NM, Johnson DW. Recent clinical trials of phar-
macologic  cardiovascular  interventions  in  patients  with  chronic 
kidney disease. Rev Recent Clin Trials. 2008; 3: 79-88. 
16.  Reddy Vanga S, Good M, Howard PA, et al. Role of vitamin D in 
cardiovascular health. Am J Cardiol. 2010; 106: 798-805. 
17.  Santoro D, Gitto L, Ferraro A, et al. Vitamin D status and mortality 
risk  in  patients  with  chronic  kidney  disease.  Ren  Fail.  2011;  33: 
184-91. 
18.  Teng M, Wolf M, Ofsthun MN, et al. Activated Injectable Vitamin D 
and Hemodialysis Survival: A Historical Cohort Study. J Am Soc 
Nephrol. 2005; 16: 1115-25. 
19.  Wolf M,  Shah  A,  Gutierrez O,  et al.  Vitamin  D  levels  and  early 
mortality among incident hemodialysis patients. Kidney Int. 2007; 
72: 1004-13. 
20.  Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardio-
vascular disease. Am J Med Sci. 2009; 338: 40-4. 
21.  Teng M, Wolf M, Lowrie E, et al. Survival of Patients Undergoing 
Hemodialysis with Paricalcitol or Calcitriol Therapy. N Engl J Med. 
2003; 349: 446-56. 
22.  Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemo-
dialysis patients receiving different vitamin D analogs. Kidney Int. 
2006; 70: 1858-65. 
23.  Tentori F, Albert JM, Young EW, et al. The survival advantage for 
haemodialysis  patients  taking  vitamin  D  is  questioned:  findings 
from the Dialysis Outcomes and Practice Patterns Study. Nephrol 
Dial Transplant. 2009; 24: 963-72. 
24.  Rajasree S, Rajpal K, Kartha CC, et al. Serum 25-hydroxyvitamin D3 
levels  are  elevated  in  South  Indian  patients  with  ischemic  heart 
disease. Eur J Epidemiol. 2001; 17: 567-71. 
25.  Mathew S, Lund RJ, Chaudhary LR, et al. Vitamin D receptor acti-
vators can protect against vascular calcification. J Am Soc Nephrol. 
2008; 19: 1509-19. 
26.  Kunitomo M, Kinoshita K, Bandô Y. Experimental atherosclerosis in 
rats fed a vitamin D, cholesterol-rich diet. J Pharmacobiodyn. 1981; 
4: 718-23. 
27.  Reis JP, Michos ED, von Mühlen D, et al. Differences in vitamin D 
status as a possible contributor to the racial disparity in peripheral 
arterial disease. Am J Clin Nutr. 2008; 88: 1469-77. 
28.  Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast 
growth factor, FGF-23, preferentially expressed in the ventro-lateral 
thalamic nucleus of the brain. Biochem Biophy Res Comm. 2000; 
277: 494-8. 
29.  Nitta  K.  Relationship  between  Fibroblast  Growth  Factor-23  and 
Mineral Metabolism in Chronic Kidney Disease. Int J Nephrol 2010; 
2010: 167984. 
30.  Brownstein CA, Zhang J, Stillman A, et al. Increased bone volume 
and  correction  of  HYP  mouse  hypophosphatemia  in  the 
Klotho/HYP mouse. Endocrinology. 2010; 151: 492-501. 
31.  Hughes SE. Differential expression of the fibroblast growth factor 
receptor (FGFR) multigene family in normal human adult tissues. J 
Histochem Cytochem. 1997; 45: 1005-19. 
32.  Kurosu  H,  Ogawa  Y,  Miyoshi  M,  et  al.  Regulation  of  fibroblast 
growth factor-23 signaling by klotho. J Biol Chem. 2006; 281: 6120-3. 
33.  Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 Do not Medi-
ate Renal Effects of FGF23. J Am Soc Nephrol. 2008; 19: 2342-50. 
34.  Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho 
and FGF receptor 1 in hyperplastic parathyroid glands from uremic 
patients. Kidney Int. 2010; 77: 232-8. 
35.  Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis 
by the phosphatonins and other novel mediators. Pediatr Nephrol. 
2008; 23: 1203-10. 
36.  Saito  H, Kusano  K, Kinosaki M,  et al.  Human  fibroblast  growth 
factor-23 mutants suppress Na+-dependent phosphate co-transport 
activity  and  1alpha,  25-dihydroxyvitamin  D3  production.  J  Biol 
Chem. 2003; 278: 2206-11. 
37.  Bai  X, Miao D,  Li  J,  Goltzman D, Karaplis  AC.  Transgenic mice 
overexpressing human fibroblast growth factor 23 (R176Q) deline-
ate  a  putative  role  for  parathyroid  hormone  in  renal  phosphate 
wasting disorders. Endocrinology. 2004; 145: 5269-79. Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
670 
38.  Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 
1,25-dihydroxyvitamin D in vascular calcification and mortality in 
fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18: 
2116-24. 
39.  Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of an-
ti-FGF23 antibodies  in hypophosphatemic  rickets/osteomalacia.  J 
Bone Miner Res. 2009; 24: 1879-88. 
40.  ADHR  Consortium.  Autosomal  dominant  hypophosphataemic 
rickets is associated with mutations in FGF23. Nat Genet. 2000; 26: 
345-8. 
41.  Perwad  F,  Zhang  MY,  Tenenhouse  HS,  et  al..  Fibroblast  growth 
factor 23 impairs phosphorus and vitamin D metabolism in vivo 
and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expres-
sion in vitro. Am J Physiol Renal Physiol. 2007; 293: F1577-83. 
42.  Jüppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of 
renal phosphate handling? J Bone Miner Res. 2010; 25: 2091-7. 
43.  Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol. 2010; 
25: 603-8. 
44.  Levine BS, Kleeman CR, Felsenfeld AJ. The journey from vitamin 
D-resistant rickets to the regulation of renal phosphate transport. 
Clin J Am Soc Nephrol. 2009; 4: 1866-77. 
45.  Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is 
elevated  before  parathyroid  hormone  and  phosphate  in  chronic 
kidney disease. Kidney Int. 2011; 79: 1370-8. 
46.  Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 
23 and left ventricular hypertrophy in chronic kidney disease. Cir-
culation. 2009; 119: 2545-52. 
47.  Shimada  T,  Urakawa  I,  Isakova  T,  et  al.  Circulating  fibroblast 
growth factor 23 in patients with end-stage renal disease treated by 
peritoneal dialysis is intact and biologically active. J Clin Endocrinol 
Metab. 2010; 95: 578-85. 
48.  Bacchetta J, Dubourg L, Harambat J, et al. The influence of glomer-
ular filtration rate and age on fibroblast growth factor 23 serum 
levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 
2010; 95: 1741-8. 
49.  Westerberg PA, Linde T, Wikström B, et al. Regulation of fibroblast 
growth  factor-23  in  chronic  kidney  disease.  Nephrol  Dial  Trans-
plant. 2007; 22: 3202-7. 
50.  Perwad F, Azam N, Zhang MY, et al. Dietary and serum phospho-
rus  regulate  fibroblast  growth  factor  23  expression  and 
1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005; 
146: 5358-64. 
51.  Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regu-
late fibroblast growth factor-23 in K-562 cells. Am J Physiol Endo-
crinol Metab. 2005; 288: E1101-9. 
52.  Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated 
by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol 
Chem. 2005; 280: 2543-9. 
53.  Stubbs JR, Egwuonwu S. Is fibroblast growth factor 23 a harbinger 
of mortality in CKD? Pediatr Nephrol. 2011; [Epub ahead of print]. 
54.  Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth 
factor 23 and mortality among patients undergoing hemodialysis. N 
Engl J Med. 2008; 359: 584-92. 
55.  Oliveira RB, Moysés RM. FGF-23: state of the art. J Bras Nefrol. 2010; 
32: 323-31. 
56.  Tamei N, Ogawa T, Ishida H, et al. Serum fibroblast growth fac-
tor-23  levels  and  progression  of  aortic  arch  calcification  in 
non-diabetic  patients  on  chronic  hemodialysis.  J  Atheroscler 
Thromb. 2011; 18: 217-23. 
57.  Razzaque MS, St-Arnaud R, Taguchi T,et al. FGF-23, vitamin D and 
calcification: the unholy triad. Nephrol Dial Transplant. 2005; 20: 
2032-5. 
58.  Wesseling-Perry K, Pereira RC, Wang H, et al. Relationship between 
plasma fibroblast growth factor-23 concentration and bone miner-
alization in children with renal failure on peritoneal dialysis. J Clin 
Endocrinol Metab. 2009; 94: 511-7. 
59.  Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 
mitigates hyperphosphatemia but accentuates calcitriol deficiency 
in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205-15. 
60.  Komaba H, Fukagawa M. FGF23: a key player in mineral and bone 
disorder in CKD. Nefrologia. 2009; 29: 392-6. 
61.  Fliser D,  Kollerits  B,  Neyer U,  et al.  Fibroblast  growth  factor 23 
(FGF23) predicts progression of chronic kidney disease: the Mild to 
Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 
18: 2600-8. 
62.  Ix JH, Shlipak MG, Wassel CL, et al. Fibroblast growth factor-23 and 
early  decrements  in  kidney  function:  the  Heart  and  Soul  Study. 
Nephrol Dial Transplant. 2010; 25: 993-7. 
63.  Hagström  E,  Hellman  P,  Larsson  TE,  et  al.  Plasma  parathyroid 
hormone and the risk of cardiovascular mortality in the community. 
Circulation. 2009; 119: 2765-71. 
64.  Coen G, Mantella D, Sardella D, et al. Asymmetric dimethylarg-
inine, vascular calcifications and parathyroid hormone serum levels 
in hemodialysis patients. J Nephrol. 2009; 22: 616-22. 
65.  Song  GJ,  Fiaschi-Taesch  N,  Bisello  A.  Endogenous  parathyroid 
hormone-related  protein  regulates  the  expression  of  PTH  type  1 
receptor  and  proliferation  of  vascular  smooth  muscle  cells.  Mol 
Endocrinol. 2009; 23: 1681-90. 
66.  Cha H, Jeong HJ, Jang SP, et al. Parathyroid hormone accelerates 
decompensation  following  left ventricular hypertrophy.  Exp Mol 
Med. 2010; 42: 61-8. 
67.  Di  Leo  C,  Gallieni  M,  Bestetti  A,  et  al.  Cardiac  and  pulmonary 
calcification in a hemodialysis patient: partial regression 4 years af-
ter parathyroidectomy. Clin Nephrol. 2003; 59: 59-63. 
68.  Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for 
the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 
1994; 4: 1814-9. 
69.  Nishizawa Y, Miki T, Okui Y, et al. Deranged metabolism of lipids 
in  patients with  chronic renal failure: possible  role  of secondary 
hyperparathyroidism. Jpn J Med. 1986; 25: 40-5. 
70.  Ogard  CG,  Engelmann  MD,  Kistorp  C,  et  al.  Increased  plasma 
N-terminal pro-B-type natriuretic peptide and markers of inflam-
mation  related  to  atherosclerosis  in  patients  with  primary  hy-
perparathyroidism. Clin Endocrinol (Oxf). 2005; 63: 493-8. 
71.  De Boer IH, Gorodetskaya I, Young B, et al.. The severity of sec-
ondary  hyperparathyroidism  in  chronic  renal  insufficiency  is 
GFR-dependent,  race-dependent,  and  associated  with  cardiovas-
cular disease. J Am Soc Nephrol. 2002; 13: 2762-9. 
72.  Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and 
diastolic  function  in  mild  primary  hyperparathyroidism.  J  Clin 
Endocrinol Metab. 2010; 95: 2172-9. 
73.  Zisman AL, Wolf M. Recent advances in the rapidly evolving field 
of fibroblast growth factor 23 in chronic kidney disease. Curr Opin 
Nephrol Hypertens. 2010; 19: 335-42. 
74.  Zoccali  C.  FGF-23  in  dialysis  patients:  ready  for  prime  time? 
Nephrol Dial Transplant. 2009; 24: 1078-81. 
75.  Shimada  T,  Kakitani M, Yamazaki  Y,  et al. Targeted  ablation  of 
Fgf23  demonstrates  an  essential  physiological  role  of  FGF23  in 
phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8. 
76.  Krajisnik T, Björklund P, Marsell R, et al. Fibroblast growth fac-
tor-23 regulates parathyroid hormone and 1alpha-hydroxylase ex-
pression in cultured bovine parathyroid cells. J Endocrinol. 2007; 
195: 125-31. 
77.  Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is 
a target organ for FGF23 in rats. J Clin Invest. 2007; 117: 4003-8. 
78.  Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth 
factor (FGF)-23 in patients with primary hyperparathyroidism. Eur 
J Endocrinol. 2004; 151: 55-60. 
79.  Wesseling-Perry  K,  Salusky  I.  Redefining  the  pathogenesis  of 
CKD-MBD: the critical role of FGF-23. Bol Pediatr. 2010; 50: 11-6. 
80.  Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and 
disease. J Am Soc Nephrol. 2005; 16: 2565-75. 
81.  Razzaque MS. Does FGF23 toxicity influence the outcome of chronic 
kidney disease? Nephrol Dial Transplant. 2009; 24: 4-7. 
82.  Butler  KG.  Hemoglobin  levels,  cardiovascular  disease,  and  left 
ventricular  hypertrophy  in  patients  with  chronic  kidney  disease. 
Case study of the anemic patient. Nephrol Nurs J. 2002; 29: 189-92. 
83.  Paoletti E, Bellino D, Gallina AM, et al. Is left ventricular hypertro-
phy a powerful predictor of progression to dialysis in chronic kid-
ney disease? Nephrol Dial Transplant. 2011; 26: 670-7. 
84.  Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular 
hypertrophy in the predialysis population: identifying opportuni-
ties for intervention. Am J Kidney Dis. 1996; 27: 347-54. Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
671 
85.  Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in 
the renal patient. J Am Soc Nephrol. 2001; 12: 1079-84. 
86.  Cerasola G, Nardi E, Palermo A, et al. Epidemiology and patho-
physiology of left ventricular abnormalities in chronic kidney dis-
ease: a review. J Nephrol. 2011; 24: 1-10. 
87.  Nakai K, Komaba H, Fukagawa M. New insights into the role of 
fibroblast growth factor 23 in chronic kidney disease. J Nephrol. 
2010; 23: 619-25. 
88.  Negishi K, Kobayashi M, Ochiai I, et al. Association between fibro-
blast growth factor 23 and left ventricular hypertrophy in mainte-
nance hemodialysis patients. Comparison with B-type natriuretic 
peptide and cardiac troponin T. Circ J. 2010; 74: 2734-40. 
89.  Liu P, Bai X, Wang H, et al. Hypophosphatemia-mediated hypo-
tension  in  transgenic  mice  overexpressing  human  FGF-23.  Am  J 
Physiol Heart Circ Physiol. 2009; 297: H1514-20. 
90.  Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular 
hypertrophy. J Clin Invest. 2011; 121: 4393-408. 
91.  Peiskerová  M,  Kalousová  M,  Kratochvílová  M,  et  al.  Fibroblast 
growth  factor  23  and  matrix-metalloproteinases  in  patients  with 
chronic  kidney  disease:  are  they  associated  with  cardiovascular 
disease? Kidney Blood Press Res. 2009; 32: 276-83. 
92.  Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion 
molecules, and all-cause and cardiovascular mortality in patients 
with  ESRD:  searching  for  the  best  risk  marker  by  multivariate 
modeling. J Am Soc Nephrol. 2005; 16: S83-8. 
93.  Stenvinkel P. Endothelial dysfunction and inflammation-is there a 
link? Nephrol Dial Transplant. 2001; 16: 1968-71. 
94.  Kojima F, Uchida K, Ogawa  T,  et al.  Plasma  levels  of fibroblast 
growth  factor-23  and  mineral  metabolism  in  diabetic  and 
non-diabetic patients on chronic hemodialysis. Int Urol Nephrol. 
2008; 40: 1067-74. 
95.  Manghat  P,  Fraser  WD,  Wierzbicki  AS,  et  al.  Fibroblast  growth 
factor-23  is  associated  with  C-reactive  protein,  serum  phosphate 
and bone mineral density in chronic kidney disease. Osteoporos Int. 
2010; 21: 1853-61. 
96.  Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast growth 
factor-23 is associated with vascular dysfunction in the community. 
Atherosclerosis. 2009; 205: 385-90. 
97.  Balci M, Kirkpantur A, Gulbay M, et al. Plasma fibroblast growth 
factor-23  levels  are  independently  associated  with  carotid  artery 
atherosclerosis  in  maintenance  hemodialysis  patients.  Hemodial 
Int. 2010; 14: 425-32. 
98.  Hu MC, Shi M, Zhang J, et al. Klotho Deficiency Causes Vascular 
Calcification in Chronic Kidney Disease. J Am Soc Nephrol. 2011; 
22: 124-36. 
99.  Donate-Correa  J,  Mora-Fernández  C,  Martínez-Sanz  R,  et  al.  Ex-
pression of FGF23/KLOTHO system in human vascular tissue. Int J 
Cardiol 2011; [Epub ahead of print]. 
100. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 rela-
tionship  to  dietary  phosphate  and  renal  phosphate  handling  in 
healthy young men. J Clin Endocrinol Metab. 2005; 90: 1519-24. 
101. Antoniucci  DM,  Yamashita  T,  Portale  AA.  Dietary  phosphorus 
regulates  serum  fibroblast  growth  factor-23  concentrations  in 
healthy men. J Clin Endocrinol Metab. 2006; 91: 3144-9. 
102. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH 
and FGF23 in normophosphatemic CKD patients: a new target in 
CKD-MBD therapy? Clin J Am Soc Nephrol. 2010; 5: 286-91. 
103. Gonzalez-Parra M, Gonzalez-Casaus ML, Galán A, et al. Lantha-
num carbonate reduces FGF23 in chronic kidney disease Stage 3 
patients. Nephrol Dial Transplant. 2011; 26: 2567-71. 
104. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and 
survival on hemodialysis. J Am Soc Nephrol. 2009; 20: 388-96. 
105. Wetmore JB, Liu S, Krebill R, et al. Effects of cinacalcet and concur-
rent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc 
Nephrol. 2010; 5: 110-6. 
106. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 
alleviates  hypophosphatemia  by  inhibiting  FGF23-FGFR-Klotho 
complex formation. Proc Natl Acad Sci USA. 2010; 107: 407-12. 
107. Economidou D, Dovas S, Papagianni A, et al. FGF-23 Levels before 
and after Renal Transplantation. J Transplant. 2009; 2009: 379082. 
108. Evenepoel  P,  Meijers  BK,  de  Jonge  H,  et  al.  Recovery  of  hyper-
phosphatoninism  and  renal  phosphorus  wasting  one  year  after 
successful renal transplantation. Clin J Am Soc Nephrol. 2008; 3: 
1829-36. 